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Introduction: Glutamine supplementation is supposed to reduce mortality and nosocomial infections in critically ill
patients. However, the recently published reducing deaths due to oxidative stress (REDOX) trials did not provide
evidence supporting this. This study investigated the impact of glutamine-supplemented nutrition on the outcomes of
critically ill patients using a meta-analysis.
Methods: We searched for and gathered data from the Cochrane Central Register of Controlled Trials, MEDLINE,
Elsevier, Web of Science and ClinicalTrials.gov databases reporting the effects of glutamine supplementation on
outcomes in critically ill patients. We produced subgroup analyses of the trials according to specific patient
populations, modes of nutrition and glutamine dosages.
Results: Among 823 related articles, eighteen Randomized Controlled Trials (RCTs) met all inclusion criteria. Mortality
events among 3,383 patients were reported in 17 RCTs. Mortality showed no significant difference between glutamine
group and control group. In the high dosage subgroup (above 0.5 g/kg/d), the mortality rate in the glutamine group
was significantly higher than that of the control group (relative risk (RR) 1.18; 95% confidence interval (CI), 1.02 to 1.38;
P= 0.03). In 15 trials, which included a total of 2,862 patients, glutamine supplementation reportedly affected the
incidence of nosocomial infections in the critically ill patients observed. The incidence of nosocomial infections
in the glutamine group was significantly lower than that of the control group (RR 0.85; 95% CI, 0.74 to 0.97;
P = 0.02). In the surgical ICU subgroup, glutamine supplementation statistically reduced the rate of nosocomial
infections (RR 0.70; 95% CI, 0.52 to 0.94; P = 0.04). In the parental nutrition subgroup, glutamine supplementation
statistically reduced the rate of nosocomial infections (RR 0.83; 95% CI, 0.70 to 0.98; P = 0.03). The length of
hospital stay was reported in 14 trials, in which a total of 2,777 patients were enrolled; however, the patient
length of stay was not affected by glutamine supplementation.
Conclusions: Glutamine supplementation conferred no overall mortality and length of hospital stay benefit in
critically ill patients. However, this therapy reduced nosocomial infections among critically ill patients, which
differed according to patient populations, modes of nutrition and glutamine dosages.Introduction
Glutamine is the most abundant plasma and intracellular
amino acid. It is known as an essential nutrient for the
gastrointestinal tract during critical illness. The efflux of
glutamine from the skeletal muscles serves as a carrier of
nitrogen to the small intestine [1]. Increased glutamine* Correspondence: haiboq2000@gmail.com
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reproduction in any medium, provided the oruse occurs during critical illness, which causes a signifi-
cant glutamine deficiency and oftentimes results in an im-
paired immune response to infections [2]. Lower plasma
and skeletal muscle glutamine levels have been associated
with immune dysfunction [3] and a higher mortality rate
in critically ill patients [4].
In animal studies [5], glutamine decreased gut mucosal
atrophy when supplemented in the parenteral nutrition that
was administered to the animals. In addition, glutamine
also reduced bacterial translocation in additional animal
models [6]. Some animal studies [7,8] also demonstratedtd. This is an open access article distributed under the terms of the Creative
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perimental models of sepsis.
In a human study [9], supplementation of enteral and
parental nutrition with glutamine was observed to im-
prove immunologic function and preserve intestinal
morphology and function. In addition, glutamine supple-
mentation may also reduce bacterial translocation [10].
Recent clinical studies [11-13] have suggested that par-
enteral administration of glutamine to ICU patients re-
duces mortality and the incidence of new infections.
However, these studies were conducted in small trials,
many of which were of poor quality. Recently, two large
trials [14,15] reported the administration of glutamine
supplementation during critical illness, but did not pro-
vide similar evidence for a benefit from glutamine sup-
plementation. Heyland et al., in the Reducing Deaths
due to Oxidative Stress (REDOX) study [14], observed
significantly increased in-hospital and six-month mortal-
ity rates with the use of glutamine, without reducing the
nosocomial infection rate in ICU patients. The aim of
this meta-analysis was to examine whether glutamine
supplementation in ICU patients reduces mortality, the
occurrence of nosocomial infections and the length of
hospital stay.Material and methods
Inclusion criteria
We included trials with the following features:
1. Type of studies: randomized controlled clinical trials
2. Population: adult ICU patients
3. Intervention: intravenous or enteral glutamine
supplementation
4. Placebo alone or no intervention
5. The following outcomes were included: a) primary
outcomes: in-hospital mortality, or if not reported, ICU/
28-day/mortality; b) secondary outcomes: six-month
mortality, nosocomial infection and length of hospital
stay.Search strategy for the identification of studies
We conducted a search of the following databases:
Medline (1948 to April 2013), Elsevier, Cochrane (Cen-
tral) database, Web of Science and ClinicalTrials.gov.
As search terms for each database, the following key-
words were used: ‘glutamine’ or ‘glutamine dipeptides’
or ‘L–glutamine’ or ‘glutamine supplementation’ and
‘critical care’ or ‘critical patients’ or ‘critical ill’ or ‘crit-
ically ill patients’ or ‘critical illness’ or ‘serious illness’
or ‘seriously ill’ or ‘intensive care units’ or ‘intensive
care’ or ‘surgical intensive care unit or ‘SICU’ or crit-
ical care medicine.’ An additional DOCX file shows
this in more detail [see Additional file 1].Study selection
Two reviewers independently screened titles and ab-
stracts to determine whether a particular study met the
inclusion criteria. The full texts of the articles were then
reviewed independently according to the inclusion and
exclusion criteria. Any discrepancies were resolved by
reaching a consensus on the inclusion or exclusion of a
particular study following a discussion with a third
reviewer.
Data extraction and management
Two reviewers independently extracted data using a
standardized data extraction protocol. Any disagree-
ments between the two reviewers were resolved by a dis-
cussion, whereby a consensus was then reached.
Some parameters, such as the mean glutamine dosage,
were estimated from other available parameters. Some
mean and standard deviations of the patients’ length of
hospital stay data were estimated according to the
method described by Hozo [16].
Methodological quality assessment
The Jadad score was constructed by adding the elements
of the use of the analysis and the blinded endpoint as-
sessments. For each item from the resulting list, we
assigned two points if the criterion was fulfilled, one
point if the corresponding information was of insufficient
detail and no points if the criterion was not fulfilled. We
used the information if it met the methodological quality
criteria. In addition, we assessed the risk of bias to
guide sensitivity analyses and to explore the sources of
heterogeneity.
Statistical analysis
We selected hospital mortality as our primary outcome
measure. If this outcome was not obtained, we preferen-
tially used the outcomes in the following order: 28-day
mortality and ICU mortality. The other outcome meas-
ure was the incidence rate of nosocomial infections,
mortality at six months and the length of stay.
We analyzed data from the included studies using Re-
view Manager (Review Manager, version 5.2). We calcu-
lated a pooled risk ratio for dichotomous data and mean
differences for continuous data with 95% confidence in-
tervals (CIs). The statistical heterogeneity of the data
was explored and quantified by the Mantel-Haenszel
chi-square test and the I2 test. Any obvious heterogen-
eity was predefined as P <0.05 with the Mantel-Haenszel
chi-square test or an I2 >50%. A publication bias was
assessed using funnel plot techniques.
Subgroup meta-analyses
Subgroup meta-analyses were performed to determine
the summary effect estimates of glutamine in specific
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mixed ICU), effects relative to a specific dosage (above
0.5 g/kg/day, between 0.3 g/kg/day and 0.5 g/kg/day,
below 0.3 g/kg/day) and the effect of the mode of nu-
tritional supplementation (parental nutrition, enteral
nutrition or a combination of the two).
Results
Study location and selection
We identified a total 823 titles and abstracts after the pri-
mary search. Of these 823 items, 245 records remained
after duplicates were removed. Based on their abstracts,
223 articles were determined to be non-relevant and were,
therefore, excluded. The remaining 22 articles were re-
trieved for an eligibility assessment, four of which were
deemed to be ineligible and were, therefore, excluded
(Figure 1).
Summary of studies
We included eighteen trials that compared glutamine sup-
plementation with a placebo in ICU patients. Three trials
were conducted in medical ICUs, eight in surgical ICUs
and seven in mixed ICUs. High-dose glutamine (above
0.5 g/kg/day) was used in six trials, and four trails used
glutamine at doses less than 0.3 g/kg /day; the other eight
trails used glutamine at doses between 0.3 g/kg/day and
0.5 g/kg/day. Six studies used glutamine supplementation
in which the patients were fed enterally, ten studies
supplemented patients with glutamine by parentalFigure 1 Flow diagram of the meta-analysis.feeding, while the patients were fed using a combin-
ation of the two methods in the other two studies. An
additional DOCX file shows this in more detail [see
Additional file 2].
The overall description of the target population, a clear
description of nosocomial infections, exclusion criteria,
clinical condition and severity of the disease are summa-
rized in Additional files [see Additional files 3, 4, 5].
The impact on mortality
The overall effect of glutamine supplementation on the
mortality rates was estimated from 17 trials, which in-
cluded a total of 3,383 patients (Figure 2). We detected
no evidence of a publication bias after a funnel plot ana-
lysis (Figure 3), and the heterogeneity was also deter-
mined to be non-significant (P = 0.26, I2 = 17%). Hospital
mortality and six-month mortality were not significantly
different between glutamine group and control group
(RR 1.01; 95% CI, 0.86 to 1.19; P = 0.87; RR 0.97; 95% CI,
0.79 to 1.19; P = 0.78) (Figure 2).
Subgroup analyses of specific patient populations
To determine the effect of glutamine on mortality in
specific patient populations, we performed subgroup
analyses of the trials according to whether the patients
were in a medical ICU, a mixed ICU or a surgical ICU.
There was a trend toward reduced mortality among pa-
tients who received glutamine as compared with patients
who did not receive glutamine (10.8% versus14.4%; RR
Figure 2 The effect of glutamine supplementation on mortality in critically ill patients (fixed effects modes). Gln: glutamine.
Figure 3 Funnel plot of the published studies in relation to the mortality meta-analysis (17 studies).
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tistically significant (P = 0.27). In the medical ICU and
mixed ICU subgroups, however, there was no significant
difference in mortality between the glutamine group and
the control group (see Additional file 2, Figure 4).
Subgroup analyses of the modes of nutritional
supplementation
To explore the effect of glutamine on mortality in ICU
patients with different modes of nutritional supplemen-
tation, we evaluated subgroup analyses of the trials accord-
ing to whether the patients were given enteral nutrition or
parental nutrition. In three subgroups, there was no signifi-
cant difference in mortality between patients who received
glutamine and patients who did not receive glutamine (see
Additional file 2, Figure 5).
A subgroup analysis of different glutamine dosages
To determine the effect on mortality of different dosages
of glutamine that were given to ICU patients, we did a
subgroup analysis of the trials according to glutamineFigure 4 A subgroup meta-analysis of the effect of glutamine in specifidosages (above 0.5 g/kg/day, between 0.3 g/kg/day and
0.5 g/kg/day and below 0.3 g/kg/day). In the high dosage
subgroup (above 0.5 g/kg/day), the mortality rate in the
glutamine group was significantly higher than that of the
control group (33.5% versus 28.2%; RR 1.18; 95% CI,
1.02 to 1.38; P = 0.03). In the other two subgroups, how-
ever, no difference was found in the treatment effect on
mortality between the glutamine and control groups (see
Additional file 2, Figure 6).
Impact on nosocomial infections
To estimate the overall effect of glutamine supplementa-
tion on the incidence rate of nosocomial infections, 15
trials, which included 2,862 patients, were evaluated
(Figure 7). No evidence of a publication bias was ob-
served following a funnel plot assessment (Figure 8), but
the heterogeneity was obvious (P = 0.01, I2 = 51%). The
incidence of nosocomial infections in the glutamine
group was significantly lower than that of the control
group (RR 0.85; 95% CI, 0.74 to 0.97; P = 0.02). We per-
formed a subgroup analysis of the trials according toc patient populations on the mortality rate (fixed effects modes).
Figure 5 A subgroup meta-analysis of the effect of glutamine supplementation in different nutritional modes on the mortality rate in
critically ill patients (fixed effects modes).
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or mixed ICU). In the surgical ICU subgroup, glutamine
supplementation statistically reduced the rate of nosoco-
mial infections (44.7% versus 60.2%; RR 0.70; 95% CI,
0.52 to 0.94; P = 0.04). However, in the medical ICU and
mixed ICU subgroups, no statistically significant differ-
ence was found between the glutamine group and the
control group (Figure 9). Then we evaluated subgroup
analyses of the trials according to mode of nutritional
supplementation. In the parental nutrition subgroup,
glutamine supplementation statistically reduced the rate
of nosocomial infections (50.0% versus 55.9%; RR 0.83;
95% CI, 0.70 to 0.98; P = 0.03) (Figure 10).
Impact on the length of stay
The patient length of hospital stay was reported in 14
trials that enrolled a total of 2,777 patients. We detected
no evidence of a publication bias following a funnel plot
assessment (Figure 11), but the heterogeneity was sig-
nificantly different (P <0.00001, I2 = 96%). No differencewas found between the groups with respect to the length
of hospital stay (WMD, -1.48 days; 95% CI, -3.93 to 0.98;
P = 0.24) (Figure 12).
Discussion
Similar to previous meta-analyses [17], glutamine supple-
mentation reduced nosocomial infections among critically
ill patients. However, unlike previous meta-analyses [17],
we found that glutamine supplementation conferred no
overall mortality benefit in critically ill patients. Further-
more, our subgroup analyses suggested that high dosage
glutamine supplementation (above 0.5 g/kg/day) signifi-
cantly increased mortality in the observed critically ill pa-
tients. In addition, we did not observe a shortening of the
length of hospital stay due to glutamine supplementation.
Glutamine depletion impairs gastrointestinal integrity
and immunologic function and is an independent prog-
nostic factor for poor outcomes in ICU patients [4]. Thus,
the investigators of some studies that provided glutamine
supplementation during critical illness expected to reduce
Figure 6 A subgroup meta-analysis of the different dosages of glutamine on mortality in critically ill patients (fixed effects modes).
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prognosis. In 1997, Griffiths et al. [18] showed that a
glutamine-containing parental solution improved the
patient six-month survival rate and reduced hospital
costs in severely ill patients. Following that study,
many future studies [11-13] suggested that supplemen-
tation of parental nutrition with glutamine decreased
nosocomial infections following a critical illness. Add-
itional studies [19-21] explored the prognostic role of
the enteral administration of supplemental glutamine
in critically ill patients; however, these findings were
rather diverse and remain unclear. Therefore, it was
suggested that, as a guideline [22], when parental nu-
trition is used in the ICU, consideration should be
given to supplement it with glutamine. However, this
viewpoint lacks the powerful evidence that is provided
by larger trials.
Disappointingly, two larger trials showed no evidence
of a benefit with glutamine as a nutritional supplement.
The SIGNET study [15] was a randomized, double-blind,
factorial, controlled trial that involved 502 ICU patients.
Its result showed no effect on the rate of nosocomialinfection incidence or on the rate of mortality when par-
enteral nutrition was supplemented with glutamine. The
problem with the SIGNET study was giving a low dose of
glutamine (20.2 g/day). The recently published REDOX
study [14], the largest trial involving glutamine supple-
mentation, suggested that glutamine supplementation was
associated with an increase in mortality without any bene-
fits for critically ill patients with multi-organ failure. How-
ever, there are problems with the REDOX study. It was
unbalanced in patients with three or more organ failures
and nutrition supplementation between glutamine and
control group. Therefore, it was urgent to reevaluate the
effect of glutamine in critically ill patients.
Many studies [4,23,24] and meta-analyses [17,25] of ran-
domized trials suggest that nutritional glutamine supple-
mentation in surgical critically ill patients may be associated
with improved survival. Our subgroup meta-analyses sug-
gested that the effect of glutamine supplementation differed
by ICU setting. Patients in surgical ICUs benefited from glu-
tamine supplementation, with the prior observation of
a reduced nosocomial infection rate and a tendency for
decreased mortality, in contrast to patients in medical
Figure 7 The effect of glutamine supplementation on the acquisition of new infections in critically ill patients (random effects modes).
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of this benefit is unclear. One possible reason may be
that surgical critically ill patients rely more on glutam-
ine because their intestinal tracts may be impaired,
and glutamine supplementation may be a primary means
of obtaining glutamine during critical illness [26-28].
However, medical ICU patients [29] and some mixed
ICU patients [30-32] can obtain glutamine from food
in addition to glutamine supplementation. Therefore,Figure 8 A funnel plot of the published studies in relation to the newenteral supplementation is only associated with a mar-
ginal effect on outcomes.
Reported studies [5,6] have suggested that both glutamine-
supplemented parenteral nutrition and enteral nutrition may
prevent bacterial translocation, but this effect may be differ-
ent between the parenteral and enteral nutrition diets. We
showed that the mortality rate of ICU patients was reduced
when parenteral nutrition was supplemented with glutamine,
but this supplementation did not provide a benefit wheninfection meta analysis (15 studies).
Figure 9 A subgroup meta-analysis of the effect of glutamine in specific patient populations on the acquisition of new infections in
critically ill patients (random effects modes).
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result is that those ICU patients with good intestinal
function can maintain good nutrition without glutam-
ine supplementation. Therefore, glutamine supplementa-
tion by parental feeding may be the primary method
of obtaining glutamine during critical illness, because
many of these patients are affected by gastrointestinal
dysfunction. Furthermore, while the dosage of glu-
tamine added by the enteral route not enough to pro-
duce a sufficient effect, it had no a favorable impact
on outcome by its influence on intestinal epithelium
and maintenance of gut integrity [22].
Lower plasma glutamine levels have been associated with
a higher mortality rate in critically ill patients [4]; however,
critical illness is not necessarily associated with a low
plasma glutamine [33]. Five RCTs [11,14,18,19,26] in our
meta-analysis examined the plasma glutamine level; pa-
tients presented with a low baseline glutamine level
(<420 μmol/L) in only two of these RCTs [18,19]. Patients
with a normal plasma glutamine level cannot benefit from
glutamine supplementation. Rodas et al. [34] discovered
that elevated baseline levels of glutamine in the plasma (avalue of >930 μmol/L) of critically ill patients was actually
associated with increased mortality. Thus, high dosage glu-
tamine supplementation caused a harmful effect, such as
high urea levels [15], instead of resulting in a benefit. Our
meta-analysis showed that glutamine supplementation at a
dosage higher than 0.5 g/kg/day increased mortality in
ICU patients, while ICU patients may only obtain a benefit
from glutamine at a dosage of between 0.3 g/kg/day and
0.5 g/kg/day. Glutamine supplementation at a higher dos-
age was used in the REDOX study, which may account for
its disadvantageous role. It is, therefore, urgent to choose
an optimal dose of glutamine, given the discrepancy among
different studies. To solve the problem, we can monitor
glutamine plasma concentration before giving glutamine to
critically ill patients. It is suggested that ICU patients be
given glutamine at a dosage of between 0.3 g/kg/day and
0.5 g/kg/day when they present with a low baseline glutam-
ine level (<420 μmol/L). Appropriate glutamine plasma
concentration would be a treatment target of glutamine
supplementation.
Some limitations of our analysis should be noted. First,
we were unable to include all relevant studies because
Figure 10 A subgroup meta-analysis of the effect of glutamine supplementation in different nutritional modes on the acquisition of
new infections in critically ill patients (random effects modes).
Figure 11 A funnel plot of published studies in relation to the hospital length of stay meta-analysis (14 studies).
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Figure 12 The effect of glutamine supplementation on the hospital length of stay in critically ill patients.
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written in English. In addition, some published trials
only reported the median and range. Using formulas, we
estimated the mean and variance of the length of stay
from the median, range and the size of the trial.Conclusions
Similar to a previous meta-analysis [17], glutamine supple-
mentation reduced nosocomial infections among critically
ill patients. However, unlike previous meta-analyses [17],
we found that glutamine supplementation conferred no
overall mortality benefit in critically ill patients. Adminis-
tration of glutamine to surgical ICU patients resulted in a
significant reduction of infectious complications and may
reduce mortality in these patients, which is in line with
previous meta-analyses. Furthermore, our subgroup ana-
lyses suggested that high dosage glutamine supplementa-
tion (above 0.5 g/kg/day) significantly increased mortality
in the observed critically ill patients. In addition, we did
not observe a shortening of the length of hospital stay due
to glutamine supplementation. The discrepancies between
the REDOX study and earlier evidence syntheses may be
due to limitations of previous trials. However, the REDOX
study is also problematic. Appropriate glutamine plasma
concentration by monitoring might be a treatment target
of glutamine supplementation. The effectiveness of glu-
tamine supplementation in critically ill patients remains
uncertain. Results from additional large-scale, high-quality
RCTs are needed.Key messages
 The effects of glutamine supplementation on
mortality differed according to patient populations,
modes of nutrition and glutamine dosages.
 Glutamine supplementation conferred no overall
mortality benefit among critically ill patients.
 Glutamine supplementation reduced nosocomial
infections among critically ill patients.
 Glutamine supplementation did not reduce the
length of stay among critically ill patients.
 Surgical patients benefited from glutamine
supplementation.
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Additional file 1: Search strategy and excluded references: the file
includes electronic database search strategy and all excluded full-text
articles.
Additional file 2: Summary of the studies included in the meta-analysis:
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glutamine dose, Jadad score and outcomes of included studies.
Additional file 3: Summary of the population included in the
meta-analysis: this file contains diagnosis and comorbidities of
included studies.
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meta-analysis: this file contains a table of exclusion criteria and
the definition of nosocomial infection of included studies.
Additional file 5: Summary of the population included in the
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of included studies.
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